文献速递前列腺增生与排尿功能障碍

欧洲注册研究:药物治疗良性前列腺增大所致下尿路症状的症状疗效与未满足需求

A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned.
PubMed 文献 · J Urol · 2020-12-01

该前瞻性注册研究在5个欧洲国家纳入2175例良性前列腺增大所致下尿路症状患者,分析1838例,随访24个月。结果显示初治患者70%、经治患者42%症状改善(IPSS降低≥3分),但两组仍有约六成患者IPSS≥8,经治组症状恶化比例更高(18.9% vs 7.8%)。

要点

  • 初治患者24个月症状改善率70%,经治患者仅42%。
  • 经治患者症状恶化(IPSS增加≥3分)比例18.9%,高于初治7.8%。
  • 24个月临床进展约1/6,手术率低于1/20,两组相近。

核心结论

  • 真实世界注册研究证实良性前列腺增大所致下尿路症状药物治疗有效,24个月临床进展约1/6、手术率低于1/20。
  • 但相当比例患者仍有明显症状,经治患者症状改善率更低且恶化比例更高,提示存在未满足的治疗需求。

研究设计与样本

  • 前瞻性注册研究,由欧洲泌尿外科学会研究基金会分析,在法国、德国、意大利、西班牙和英国5个欧洲国家的初级保健和泌尿外科转诊中心开展,随访24个月。
  • 共纳入2175例患者,分析1838例,其中初治患者575例(至少1个月未用α受体阻滞剂或至少6个月未用5α还原酶抑制剂),经治患者1263例。

主要发现

  • 注册期间90%患者坚持处方方案。
  • 24个月时,初治患者70%、经治患者42%症状改善(IPSS降低≥3分)。
  • 两组仍有症状患者(IPSS≥8)比例分别为初治59%、经治61%。
  • 症状恶化(IPSS增加≥3分)在经治患者为18.9%,初治患者为7.8%。
  • 24个月时临床进展率初治16% vs 经治17%,手术率初治5% vs 经治7%。

临床怎么用

  • 药物治疗下仍需定期评估IPSS,关注经治患者症状恶化风险。
  • 真实世界数据可用于患者咨询:多数患者症状改善,但约六成仍有IPSS≥8。
  • 24个月临床进展和手术率较低,支持药物治疗作为良性前列腺增大所致下尿路症状的管理策略。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated unmet needs of lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment by measuring symptom improvement, persistence and deterioration in real life. A prospective registry was conducted for 24 months in 5 European countries and analyzed by the European Association of Urology Research Foundation. MATERIALS AND METHODS: Previously untreated and treated patients were enrolled to the registry in both primary care and urology referral centers in France, Germany, Italy, Spain and the UK. RESULTS: Overall, 2,175 patients were enrolled with 1,838 analyzed, consisting of 575 previously untreated lower urinary tract symptoms-benign prostatic enlargement patients (no alpha blockers for at least 1 month or no 5-alpha reductase inhibitors for at least 6 months) and 1,263 previously treated patients. During the registry 90% of patients adhered to the prescribed regimen. After 24 months, 70% of previously untreated and 42% of previously treated patients experienced symptom improvement (International Prostate Symptom Score [IPSS] reduction of ≥3 points). Symptomatic patients (IPSS ≥8) remained in both groups (59% in previously untreated and 61% in previously treated), with greater symptom deterioration (IPSS increase ≥3 points) in 18.9% in previously treated vs 7.8% in previously untreated patients. Both clinical lower urinary tract symptoms-benign prostatic enlargement progression and surgery rates were similar in untreated vs treated groups at 16% vs 17% and 5% vs 7%, respectively, at 24 months. CONCLUSIONS: This prospective registry confirmed lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment effectiveness in a real-world setting, with low clinical progression observed in about 1 in 6 patients and lower surgery rates below 1 in 20, by 24 months.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tubaro A, Speakman M, de la Taille A, et al. A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. J Urol. 2020. PMID: 33259270. doi:10.1097/JU.0000000000001506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。